Benitez-Vera Valeria, Bras Dineli, Montiani-Ferreira Fabiano
Department of Ophthalmology, University of Georgia Veterinary Teaching Hospital, Athens, Georgia, USA.
Department of Ophthalmology, Centro de Especialistas Veterinarios de Puerto Rico, San Juan, Puerto Rico, USA.
Vet Ophthalmol. 2025 Mar;28(2):293-305. doi: 10.1111/vop.13208. Epub 2024 Mar 6.
To report preliminary results of MP-TSCP in canine patients with glaucoma while evaluating sweep velocity, treatment efficacy, and safety utilizing standardized surgical parameters.
Client-owned dogs that underwent MP-TSCP at a veterinary referral hospital.
Medical records of 19 eyes (14 dogs) treated with MP-TSCP were reviewed. Eleven eyes were treated with a 10 s/sweep (s) velocity and 8 eyes with a 20 s/s. Laser duty cycle was set at 31.3%, mean laser energy was 2766 mW, and mean duration was 120 s per hemisphere. Minimum post-operative follow-up was 6 months. Outcomes of intraocular pressure (IOP), vision status, degree of antiglaucoma medications, and complications were evaluated.
There was a significantly lower median (IQR) IOP (<25 mmHg) at each timepoint postoperatively compared to IOP pre-operatively (p < 0.05). The overall success rate for IOP control at 6 months was 84%, 100% for the 10 s/s and 62.5% for the 20 s/s. Vision was preserved in 10/11 (90%) eyes from the 10 s/s group and 4/8 (50%) eyes from the 20 s/s group at 6 months. Average number of glaucoma medications in the 10 s/s group decreased from 4.4 to 1.5 and from 3.3 to 2.5 in the 20 s/s group. Post-operative complications were mild and resolved within 1 week.
MP-TSCP is a non-invasive treatment alternative for canine glaucoma. Employing higher energy levels rendered long-term IOP control while retaining a high safety profile with minimal postoperative complications. There was no statistical difference between a 10 s/s and 20 s/s surgical velocity, both leading to successful surgical outcomes up to 6 months post-operatively.
报告在犬青光眼患者中进行多点经巩膜睫状体光凝术（MP-TSCP）的初步结果，同时利用标准化手术参数评估扫描速度、治疗效果和安全性。
在一家兽医转诊医院接受MP-TSCP治疗的客户拥有的犬。
回顾了19只眼（14只犬）接受MP-TSCP治疗的病历。11只眼以10秒/次扫描速度治疗，8只眼以20秒/次扫描速度治疗。激光占空比设定为31.3%，平均激光能量为2766毫瓦，每侧半球平均持续时间为120秒。术后最短随访时间为6个月。评估眼压（IOP）、视力状态、抗青光眼药物使用程度和并发症的结果。
与术前眼压相比，术后各时间点眼压中位数（四分位间距）显著降低（<25 mmHg）（p < 0.05）。6个月时眼压控制的总体成功率为84%，10秒/次扫描速度组为100%，20秒/次扫描速度组为62.5%。6个月时，10秒/次扫描速度组10/11（90%）的眼睛视力得以保留，20秒/次扫描速度组4/8（50%）的眼睛视力得以保留。10秒/次扫描速度组青光眼药物平均使用数量从4.4降至1.5，20秒/次扫描速度组从3.3降至2.5。术后并发症轻微，1周内缓解。
MP-TSCP是犬青光眼的一种非侵入性治疗选择。采用较高能量水平可实现长期眼压控制，同时保持高安全性，术后并发症最少。10秒/次和20秒/次的手术速度之间无统计学差异，两者均在术后6个月取得了成功的手术效果。
